Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2005-11-08 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Global Capital Raising Final US Prospectus 159 pages ?Kb
Regulatory Filings
2005-11-08 English
Pharmaxis announces pricing of Global Capital Raising 3 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is a media release dated 8 November 2005 from Pharmaxis Ltd announcing the pricing of a global capital raising involving an underwritten public offering of American Depositary Shares and a placement of ordinary shares. It details the number of shares, pricing, underwriters, use of proceeds, and closing dates. The content focuses on financing activities and capital raising rather than financial results, management changes, or regulatory filings. The document length is 6859 characters, which is sufficient to contain substantive information. There is no indication that this is a report or announcement of a report publication, nor is it a certification or legal proceeding. The primary subject is clearly a capital raising update, fitting the Capital/Financing Update (CAP) category.
2005-11-07 English
Trading Halt 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a market release dated 7 November 2005 from Pharmaxis Ltd announcing a trading halt requested by the company. The text references a global capital raising involving placement of shares and an initial public offer. There is no financial data, report content, or detailed analysis present. The document is an announcement related to capital raising activities and trading status, not a full report or financial statement. Given the content and context, this fits best under Capital/Financing Update (CAP). The document length is short and focused on the trading halt and capital raising announcement, not a report publication or regulatory filing. Therefore, the classification is CAP with high confidence.
2005-11-06 English
Ceasing to be a substantial holder 3 pages ?Kb
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 - Notice of ceasing to be a substantial holder, filed under the Corporations Act 2001. It details changes in substantial shareholding, including dates and nature of changes, and is signed by a director. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category Major Shareholding Notification (MRQ). The document is about a specific shareholder ceasing to be substantial due to internal reorganization and distribution of shares. It is not an annual report, earnings release, or any other financial report, but a regulatory notification about shareholding changes.
2005-11-02 English
US SEC Form F-1 Amendment No.2 249 pages ?Kb
Regulatory Filings
2005-11-02 English
Appendix 3B 9 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) announcement for new issue of securities, application for quotation of additional securities, and related agreements. It details the issuance of unlisted employee options, their terms, exercise price, expiry, and the number of securities issued. The document is focused on capital raising or share issuance activities rather than financial results or management commentary. It is not a full financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about securities issuance, consistent with a capital update filing.
2005-10-30 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.